CALR and myeloproliferative neoplasm: By means of the proposed method, we found that, while NETosis level in healthy donors does not exceed 9%, the levels of NETosis in the pediatric patients with MPN varies from 6% for the patients without determined mutation to 60% in the patient with CALR-associated MPN (Figure 3).